EOS006215 for Cancer

Recruiting in Palo Alto (17 mi)

+8 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: iTeos Belgium SA

No Placebo Group

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?TRM-010 is a first-in-human (FIH) clinical study designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of EOS006215, a fully human monoclonal antibody that binds to the triggering receptor expressed on myeloid cells 2 (TREM2). The study includes EOS006215 monotherapy and combination therapy with other anticancer agents in participants with advanced solid tumors.

Eligibility Criteria

This trial is for adults with advanced solid tumors, including uterine tumors, who have not responded to standard treatments. Participants must be able to receive injections or infusions and have measurable disease as per certain criteria.

Inclusion Criteria

My advanced cancer has no standard treatment options left for me.

At least one tumor lesion measurable per RECIST v1.1

Have an estimated minimum life expectancy of ≥ 12 weeks

+3 more

Exclusion Criteria

Pregnant or breastfeeding

I haven't had cancer treatment or experimental drugs in the last 3 weeks.

I haven't had major surgery in the last 5 weeks or minor surgery in the last 7 days.

+9 more

Participant Groups

The study tests EOS006215, a new antibody targeting TREM2 on myeloid cells. It's given alone or with Pembrolizumab/other cancer drugs. The phases assess safety, dosage levels (Phase I), and its effect on tumor size (Phase Ib).

2Treatment groups

Experimental Treatment

Group I: Part 1 Dose Escalation (Monotherapy)Experimental Treatment1 Intervention

EOS006215 dose escalation as monotherapy

Group II: Part 1 Dose Escalation (Combination Therapy)Experimental Treatment2 Interventions

EOS006215 dose escalation in combination with pembrolizumab or with other anticancer agents